P3-207: Prognostic impact of platelet counts on survival after surgery in stage I non small cell lung cancer  by Aerts, Joachim G.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS768
University, Faculty of Medicine, Department of Chest Diseases, Izmir, 
Turkey 
Purpose: To report the long term results of adjuvant radiotherapy in 
resected non small cell lung cancer patients.
Methods And Materials: We retrospectively reviewed the medical 
records of 100 non small cell lung carcinoma patients ( 93 men and 7 
women; median age 58, range 35-75) who received adjuvant radio-
therapy between January 1994 and December 2004 at Ege University 
Department of Radiotherapy. The most frequently performed surgical 
procedure was lobectomy (62), followed by pneumonectomy (25), 
wedge resection (7) and bilobectomy (6). The patients were pathologi-
cally staged. Radiotherapy was delivered to patients with positive 
margins or following a wedge resection in stage I disease. Nine patients 
received platinum-based neoadjuvant chemotherapy prior to surgery. 
Nineteen patients received adjuvant chemotherapy prior to radiotherapy 
and 22 patients received adjuvant chemotherapy after radiotherapy. 
Radiotherapy was administered to the tumor bed and/or mediastinum 
using Co 60 or 6 MV photons. The median postoperative radiotherapy 
dose was 50 Gy using conventional fractionation. 
A Kaplan-Meier estimate of local control (LC), distant metastasis free 
survival (DFS), and overall survival (OS) was calculated. 
Results: Pathologic stages included I (n =18), II (n = 45), IIIA (n = 
31), and IIIB (n = 6). After a median follow-up of 52 months (6-169) 
median survival was 61 months. The 5 and 10 years OS, LC and DFS 
rates for all patients were 50%, 77%, 36% and 34%, 65%, 9% respec-
tively. The over all survival for stages I, II and III were 58%, 55% and 
38% respectively at 5 years. Only pneumonectomy and low KPS scores 
were found to have a negative impact on survival(P= 0.01 and 0.03). 
For local contol, the total number of involved lymph nodes and KPS 
were found as signiﬁcant prognostic factors(P=0.03 for both two). For 
DFS, the only correlation was found for nodal stage(p=0.03). 
Conclusion: Surgery and postoperative radiotherapy can provide a 
high locoregional control rate (over 70%) however, the efﬁcacy of 
postoperative radiotherapy decreases with pneumonectomy, low KPS 
and greater number of involved lymph nodes. 
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Background: Brain metastases (BM) represent one of the most fre-
quent complications related to non-small lung cancer (NSCLC), and 
their treatment continues to evolve. We have evaluated the activity, 
toxicity and the impact on Quality of Life (QoL) of a concomitant treat-
ment with whole brain radiotherapy (WBRT) and Geﬁtinib in patients 
with brain metastases from NSCLC in a prospective study. 
Methods: 21 patients were enrolled and received 40 Gy/20f/4w WBRT 
with concomitant Geﬁtinib (250 mg /day). The primary end points were 
clinical symptoms and objective response. 
Results: 4 patients had a complete response, 13 patients had a partial 
response, 3 patients had stable disease, while 1 patient had progression 
disease. The overall response rate was 81.0%. The most frequent toxici-
ties included rash (85.7%) and diarrhea (42.9%), and only 3 patients 
developed a grade 3 diarrhea. Gender and the recursive partitioning 
analysis (RPA) were found to be predictive factors for response in 
patients. There were statistically signiﬁcant changes between pretreat-
ment and post-treatment in all domains of QOL but additional concerns 
with the FACT-L. 
Conclusion: We concluded that this treatment was well tolerated, with 
an encouraging objective response rate and a signiﬁcant improvement 
in quality of life. Our study found a high level of satisfaction for QoL, 
this provides useful information to share with patients in discussions 
regarding molecular targeting treatment of these lesions.
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Background: From recent studies on adjuvant chemotherapy in oper-
ated patients with non-small cell lung cancer it was established that the 
beneﬁcial effect of adjuvant therapy in stage I disease is questionable. 
But in stage I disease recurrences do appear. Identifying patients prone 
for recurrent disease would be highly desirable. A number of studies 
reported an association between thrombocytosis and survival in patients 
with lung cancer. The prognostic impact of platelet counts was tested 
in a series of patients who underwent surgery for stage I non-small cell 
lung cancer (NSCLC).
Methods: Electronic records from the Rotterdam Cancer Registry 
were used to select patients who underwent surgery for stage I NSCLC 
in two hospitals during the period 1989-2002. Information on platelet 
count and vital status was gathered retrospectively. The study group 
(n=354) was stratiﬁed by platelet count (<150, 150-225, 226-400, ≥ 
400) and variation in actuarial survival was assessed with the log-rank 
test and with proportional hazard analysis.
Results: Univariate survival analysis suggested age (p=0.12), extent 
of surgery (p=0.13) and platelet count (p=0.0003) as prognostic factors 
(table). Absolute ﬁve-year survival by platelet count subgroup was 
36%, 68%, 68% and 35%, respectively. In multivariate analysis, the 
hazard ratios for platelet count <150 and >=400 were 3.2 and 3.1, as 
compared with normal platelet counts. 
Conclusions: Low platelet counts and thrombocytosis were associated 
with poorer survival in patients with stage I NSCLC. A novel ﬁnding 
is that also low platelet counts seem to inﬂuence survival. Given the 
similarity in survival in the groups with high and low platelet counts, 
a measurement error should not be ruled out. Platelet production may 
actually have been stimulated in these patients but pseudothrombo-
cytopenia may have occurred due to platelet agglutination. Research 
regarding the biological mechanism behind this association may reveal 
new treatment options. Adjuvant therapy should be considered also in 
patients with stage I disease with abnormal platelet counts. 
